Evidence map›Paper›PMID 25555734›Full record

ArticleBioorganic & medicinal chemistry2015

Ferrocenes as potential chemotherapeutic drugs: synthesis, cytotoxic activity, reactive oxygen species production and micronucleus assay.

Wanda I Pérez, Yarelys Soto, Carmen Ortíz, Jaime Matta, Enrique Meléndez

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wanda I PérezDepartment of Chemistry, University of Puerto Rico, PO Box 9019, Mayagüez, PR 00681, United States.
Yarelys SotoDepartment of Biotechnology, University of Puerto Rico, PO Box 9019, Mayagüez, PR 00681, United States.
Carmen OrtízDepartment of Pharmacology, Toxicology and Physiology, Ponce School of Medicine and Health Sciences, Ponce, PR 00732-7004, United States.
Jaime MattaDepartment of Pharmacology, Toxicology and Physiology, Ponce School of Medicine and Health Sciences, Ponce, PR 00732-7004, United States.
Enrique MeléndezDepartment of Chemistry, University of Puerto Rico, PO Box 9019, Mayagüez, PR 00681, United States. Electronic address: enrique.melendez@upr.edu.

Funding

The Role of Midbrain to Prelimbic Cortex Glutamatergic projections in Stress-induced Drug SeekingU54MD007579 · NIMHD · PONCE SCHOOL OF MEDICINE · PI Emmanuel Antonio Cruz, Kenira J Thompson · 2019 to 2026
$35.9M
Using MC1R genotype to impact skin cancer risk behaviors in Hispanics/LatinosU54CA163068 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KENNETH Lynn WRIGHT · 2012 to 2026
$23.1M
Therapeutic Immunization in Monkey Model of AIDSS06GM008239 · NIGMS · PONCE SCHOOL OF MEDICINE · PI MATTA, JAIME L · 1989 to 2009
$21.5M
VIRAL SEQUENCES IN PEDIATRIC HIV INFECTION IN PRG12MD007579 · NIMHD · PONCE SCHOOL OF MEDICINE · PI TORRES-RUIZ, JOSE A · 2012 to 2018
$15.9M
RISE Option III: Ponce School of Medicine MBRS-RISE ProgramR25GM082406 · NIGMS · PONCE SCHOOL OF MEDICINE · PI APPLEYARD, CAROLINE B · 2008 to 2021
$9.5M
RISE Enhancing Biomedical Sciences and Biomedical Engineering in Science and TechR25GM088023 · NIGMS · UNIVERSITY OF PUERTO RICO MAYAGUEZ · PI LOPEZ-GARRIGA, JUAN · 2010 to 2013
$5.0M
Factors associated with variability in DNA repair capacity in their effect on breSC1CA182846 · NCI · PONCE SCHOOL OF MEDICINE · PI MATTA, JAIME L · 2013 to 2016
$1.5M
NCI NIH HHS 019SC1CA182846-04NCI NIH HHS 1 U54 CA163068-01A1NCI NIH HHS SC1 CA182846NCI NIH HHS U54 CA163068NIGMS NIH HHS R25 GM082406NIGMS NIH HHS R25 GM088023NIGMS NIH HHS R25GM088023NIGMS NIH HHS S06 GM008239NIGMS NIH HHS S06-GM008239-20NIMHD NIH HHS G12 MD007579NIMHD NIH HHS MD007579NIMHD NIH HHS U54 MD007579
6 · The paper itself

Abstract

Three new ferrocene complexes were synthesized with 4-(1H-pyrrol-1-yl)phenol group appended to one of the Cp ring. These are: 1,1'-4-(1H-pyrrol-1-yl)phenyl ferrocenedicarboxylate, ('Fc-(CO2-Ph-4-Py)2'), 1,4-(1H-pyrrol-1-yl)phenyl, 1'-carboxyl ferrocenecarboxylate ('Fc-(CO2-Ph-4-Py)CO2H') and 4-(1H-pyrrol-1-yl)phenyl ferroceneacetylate ('Fc-CH2CO2-Ph-4-Py'). The new species were characterized by standard analytical methods. Cyclic voltammetry experiments showed that Fc-CH2CO2-Ph-4-Py has redox potential very similar to the Fc/Fc(+) redox couple whereas Fc-(CO2-Ph-4-Py)2 and Fc-(CO2-Ph-4-Py)CO2H have redox potentials of over 400 mV higher than Fc/Fc(+) redox couple. The in vitro studies on Fc-(CO2-Ph-4-Py)2 and Fc-(CO2-Ph-4-Py)CO2H revealed that these two compounds have moderate anti-proliferative activity on MCF-7 breast cancer cell line. In contrast Fc-CH2CO2-Ph-4-Py which displayed low anti-proliferative activity. In the HT-29 colon cancer cell line, the new species showed low anti-proliferative activity. Cytokinesis-block micronucleus assay (CBMN) was performed on these ferrocenes and it was determined they induce micronucleus formation on binucleated cells and moderate genotoxic effects on the MCF-7 breast cancer cell line. There is a correlation between the IC50 values of the ferrocenes and the amount of micronucleus formation activity on binucleated cells and the reactive oxygen species (ROS) production on MCF-7 cell line.

Indexed as

Antineoplastic AgentsFerrous CompoundsHumansMCF-7 CellsMetallocenesMicronucleus TestsReactive Oxygen SpeciesStructure-Activity RelationshipAntineoplastic AgentsferroceneFerrous CompoundsMetallocenesReactive Oxygen SpeciesAnti-proliferativeCytokinesis-block micronucleus assayFerroceneHT-29MCF-10AMCF-7

Identifiers

PMID25555734
PMCPMC4330091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.